NLS Pharmaceutics (NASDAQ:NCEL) Trading Up 5.5% – What’s Next?

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) shares were up 5.5% on Wednesday . The stock traded as high as $4.25 and last traded at $4.23. Approximately 72,045 shares traded hands during trading, an increase of 204% from the average session volume of 23,728 shares. The stock had previously closed at $4.01.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of NLS Pharmaceutics in a research report on Monday, June 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

NLS Pharmaceutics Price Performance

The company’s 50-day simple moving average is $3.42 and its two-hundred day simple moving average is $2.90.

Insider Buying and Selling at NLS Pharmaceutics

In related news, Director Michel Revel bought 54,545 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average cost of $2.75 per share, for a total transaction of $149,998.75. Following the completion of the transaction, the director owned 957,530 shares of the company’s stock, valued at approximately $2,633,207.50. This trade represents a 6.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Olivier Samuel purchased 81,818 shares of the business’s stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $2.75 per share, with a total value of $224,999.50. Following the acquisition, the director directly owned 81,818 shares of the company’s stock, valued at $224,999.50. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 16.40% of the company’s stock.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.